Cargando…
When Origin Matters: Properties of Mesenchymal Stromal Cells From Different Sources for Clinical Translation in Kidney Disease
Advanced therapy medicinal products (ATMPs) offer new prospects to improve the treatment of conditions with unmet medical needs. Kidney diseases are a current major health concern with an increasing global prevalence. Chronic renal failure appears after many years of impairment, which opens a tempor...
Autores principales: | Calcat-i-Cervera, Sandra, Sanz-Nogués, Clara, O'Brien, Timothy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488400/ https://www.ncbi.nlm.nih.gov/pubmed/34616756 http://dx.doi.org/10.3389/fmed.2021.728496 |
Ejemplares similares
-
Current good manufacturing practice considerations for mesenchymal stromal cells as therapeutic agents
por: Sanz-Nogués, Clara, et al.
Publicado: (2021) -
Adipose stromal cells bioproducts as cell-free therapies: manufacturing and therapeutic dose determine in vitro functionality
por: Skovronova, Renata, et al.
Publicado: (2023) -
Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach
por: Calcat-i-Cervera, Sandra, et al.
Publicado: (2023) -
Mesenchymal stem/stromal cells: Developmental origin, tumorigenesis and translational cancer therapeutics
por: Li, Chenghai, et al.
Publicado: (2020) -
Scaffold-based delivery of mesenchymal stromal cells to diabetic wounds
por: Du, Shanshan, et al.
Publicado: (2022)